Novigenix, a Lausanne, Switzerland-based biotech company focused on Immuno-Transcriptomic oncology solutions, raised $20M in Series B funding.
The backers were not disclosed.
The company intends to use the funds to fast track the clinical validation of its second generation NGS-based liquid biopsy CRC screening assay, and development of new immunotherapy patient stratification assays. The immuno-transcriptomic cancer-specific profiles obtained from blood draws are combined with multi-modal information such as patient clinical data to predict response to therapy at baseline, and treatment monitoring following therapy.
Led by CEO Dr. Brian Hashemi, Novigenix IS data-driven precision medicine biotech company that develops and commercializes Immuno-Transcriptomic precision oncology solutions. Its Liquid Immuno-Transcriptomic (LITOseek) platform provides insights into the molecular pathways associated with onset of cancer and their response to therapy. The company has validated its approach in Colorectal Cancer (CRC) screening, and provides new molecular insights and predictive algorithms for patient stratification and monitoring of Immunotherapies.
FinSMEs
02/12/2022